Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline US Deferred Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than consolidated financial performance.
Material Changes
The filing reports an increase in American Depositary Shares (ADSs) held by Mr. D E Troy. This increase resulted from the re-investment of dividends paid to shareholders on January 3, 2013. The transaction involved 323.047 ADSs at a price of $43.98 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 8, 2013 (Notification date); January 3, 2013 (Dividend payment date).
- Individual Involved: Mr. D E Troy.
- Transaction Type: Increase in ADS holdings via dividend re-investment.
- Volume: 323.047 ADSs.
- Price: $43.98 per ADS.